PLAQUE PSORIASIS


Associated tags: Scalp, Skin, Plaque, Psoriasis, Patient, PASI, Psoriasis Area and Severity Index, Pharmaceutical industry, Dermatology, Science

Bristol Myers Squibb and Ted Danson Empower Those with Plaque Psoriasis to Take Action in “SO, Have You Found It?” Campaign

Retrieved on: 
Tuesday, March 19, 2024
Health, Other Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Psoriasis, Partnership, Patient, Neuroscience, Travel, Dermatology, Plaque, Bristol Myers Squibb, Humour, DSM-IV codes, Empowerment, System, Skin, Multimedia, FDA, Pharmaceutical industry

Award-winning actor Ted Danson, who lives with plaque psoriasis, teams up with Bristol Myers Squibb for the inspiring “ SO, Have You Found It?

Key Points: 
  • Award-winning actor Ted Danson, who lives with plaque psoriasis, teams up with Bristol Myers Squibb for the inspiring “ SO, Have You Found It?
  • View the full release here: https://www.businesswire.com/news/home/20240315988620/en/
    Actor Ted Danson and SOTYKTU patient Emily both living with moderate to severe plaque psoriasis.
  • (Photo: Bristol Myers Squibb)
    “Navigating plaque psoriasis is both deeply personal and often challenging for many patients,” acknowledged Carlos Dortrait, senior vice president and general manager of U.S. Immunology and Neuroscience at Bristol Myers Squibb.
  • Many with plaque psoriasis find themselves altering their lifestyles, sometimes avoiding social situations and personal connections.

New Data Shows ZORYVE® (Roflumilast) Cream 0.3% Provided Measurable Improvement of Plaque Psoriasis in Nearly All Individuals in DERMIS Trials

Retrieved on: 
Friday, October 20, 2023
Week, Psoriasis, Conference, Patient, PASI, Psoriasis Area and Severity Index, Pharmaceutical industry

Separately reported investigator and patient local tolerability assessment data confirms again that ZORYVE was well tolerated from first application.

Key Points: 
  • Separately reported investigator and patient local tolerability assessment data confirms again that ZORYVE was well tolerated from first application.
  • ZORYVE is a once-daily, steroid-free cream for individuals with plaque psoriasis down to 6 years of age that can be used for any duration across all affected areas of the body.
  • “Data reported from clinical trials generally show results within the overall study population which is certainly important.
  • Investigator- and Patient-Rated Local Tolerability in Phase 3 Trials of Topical Roflumilast in Patients with Psoriasis, Seborrheic Dermatitis, and Atopic Dermatitis

Janssen Highlights Latest Research for TREMFYA® (guselkumab) and Investigational Targeted Oral Peptide JNJ-2113 in Moderate to Severe Plaque Psoriasis at the European Academy of Dermatology and Venereology (EADV) Congress

Retrieved on: 
Monday, October 9, 2023
Congress, Red, Quality of life, PASI, European Academy of Allergy and Clinical Immunology, Treatment, Oral, Abstract, SPRING, Janssen, Health and Quality of Life Outcomes, Johnson & Johnson, Janssen Pharmaceuticals, Disease, Real Life, HOUSE, Psoriasis Area and Severity Index, Journal of the European Academy of Dermatology and Venereology, Macrophage, Plaque, Overalls, Safety, Science, Political moderate, Pharmaceutical industry, Medical imaging, Vaccine, Psoriasis, Dermatology, Venereology, Libido, PSO, Patient

SPRING HOUSE, Pa., Oct. 9, 2023 /PRNewswire/ -- Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, today announced that 30 company-sponsored presentations will be featured at the European Academy of Dermatology and Venereology (EADV) Congress taking place in Berlin, Germany from October 11-14, 2023. Janssen will present new data on the underlying science of the treatment of psoriasis (PsO), including results from the Phase 3b GUIDE trial highlighting early intervention with TREMFYA® (guselkumab) (Abstract #FC08.5)1 and systemic pharmacodynamica response data for JNJ-2113 from the Phase 2 FRONTIER 1 trial (Abstract #FC08.2).2

Key Points: 
  • "Patients are waiting for a new option with the goal of helping manage their plaque psoriasis symptoms, which could potentially transform the treatment paradigm.
  • The data from these presentations add to the comprehensive body of scientific evidence for our investigational and established therapies, potentially offering people living with moderate to severe plaque psoriasis much-needed relief from their symptoms."
  • A selection of Janssen-sponsored abstracts being featured at EADV is provided below.
  • Systemic pharmacodynamics is the study of the biochemical and physiologic effects of drugs in the body.

Takeda Announces Positive Results in Phase 2b Study of Investigational TAK-279, an Oral, Once-Daily TYK2 Inhibitor, in People with Moderate-to-Severe Plaque Psoriasis

Retrieved on: 
Saturday, March 18, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, TAK, Psoriasis, PASI, University, Skin, Psoriasis Area and Severity Index, American Academy of Dermatology, American Academy, MPH, Patient, AAD, TYK2, Dean (education), Pharmaceutical industry, Dermatology, Takeda

Takeda ( TSE:4502/NYSE:TAK ) today announced positive results from a Phase 2b clinical trial of TAK-279 (NDI-034858), a highly selective, oral allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate-to-severe plaque psoriasis.

Key Points: 
  • Takeda ( TSE:4502/NYSE:TAK ) today announced positive results from a Phase 2b clinical trial of TAK-279 (NDI-034858), a highly selective, oral allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate-to-severe plaque psoriasis.
  • Changes in laboratory parameters were consistent with known effects of allosteric TYK2 inhibition.1
    “These compelling TAK-279 data strengthen its potential for people with moderate-to-severe plaque psoriasis.
  • Results from the Phase 2b study have no impact on the full year consolidated reported forecast for the fiscal year ending March 31, 2023 (Fiscal Year 2022).
  • *In the TAK-279 2mg arm, the PASI 90 response rate was 8% with a nominal p-value = 0.037 compared to placebo.1

DGAP-News: MC2 Therapeutics: Almirall and MC2 Therapeutics enter a License, Collaboration and Commercialization Agreement for European Rights to Wynzora(R) Cream for treatment of Plaque Psoriasis

Retrieved on: 
Wednesday, February 17, 2021
Organ systems, Drugs, Psoriasis, Almirall, Calcipotriol/betamethasone dipropionate, Medical specialties, Plaque Psoriasis, Wynzora(R) Cream, Almirall, MC2 Therapeutics

MC2 Therapeutics: Almirall and MC2 Therapeutics enter a License, Collaboration and Commercialization Agreement for European Rights to Wynzora(R) Cream for treatment of Plaque Psoriasis

Key Points: 
  • MC2 Therapeutics: Almirall and MC2 Therapeutics enter a License, Collaboration and Commercialization Agreement for European Rights to Wynzora(R) Cream for treatment of Plaque Psoriasis
    The issuer is solely responsible for the content of this announcement.
  • Almirall and MC2 Therapeutics Enter a License, Collaboration and Commercialization Agreement for European Rights to Wynzora(R) Cream for Treatment of Plaque Psoriasis
    In this collaboration Almirall will commercialize Wynzora(R) Cream for treatment of plaque psoriasis in Europe and MC2 Therapeutics will be responsible for manufacturing and supply.
  • The treatment satisfaction score using the Psoriasis Treatment Convenience Scale (PTCS) was superior compared to Dovobet/Daivobet(R) Gel.
  • Mike Mcclellan, Chief Financial Officer (CFO) and interim Chief Executive Officer (CEO) said: "We are thrilled with this agreement with MC2 Therapeutics.

Almirall and MC2 Therapeutics enter a License, Collaboration and Commercialization Agreement for European Rights to Wynzora® Cream for treatment of Plaque Psoriasis

Retrieved on: 
Wednesday, February 17, 2021
Biotechnology, General Health, Pharmaceutical, Health, Drugs, Chemical compounds, Organ systems, Combination drugs, Antipsoriatics, Calcipotriol/betamethasone dipropionate, Corticosteroids, Calcipotriol, Betamethasone, Psoriasis, Almirall, Betamethasone dipropionate, Biotechnology, General Health, Pharmaceutical, Health, Drugs, Chemical compounds, Organ systems, Combination drugs, Antipsoriatics, Calcipotriol/betamethasone dipropionate, Corticosteroids, Calcipotriol, Betamethasone, Psoriasis, Almirall, Betamethasone dipropionate, Plaque Psoriasis, Wynzora® Cream, Almirall, MC2 Therapeutics

Almirall and MC2 Therapeutics partner to make Wynzora Cream a leading topical product for treatment of plaque psoriasis in Europe - a market, which currently is more than 25 million units in sales volume annually2.

Key Points: 
  • Almirall and MC2 Therapeutics partner to make Wynzora Cream a leading topical product for treatment of plaque psoriasis in Europe - a market, which currently is more than 25 million units in sales volume annually2.
  • Wynzora Cream (50 g/g calcipotriol and 0.5 mg/g betamethasone as dipropionate) received US FDA approval on 20th July 2020.
  • The treatment satisfaction score using the Psoriasis Treatment Convenience Scale (PTCS) was superior compared to Dovobet/Daivobet Gel.
  • Mike Mcclellan, Chief Financial Officer (CFO) and interim Chief Executive Officer (CEO) said: "We are thrilled with this agreement with MC2 Therapeutics.

DGAP-News: MC2 Therapeutics: MC2 Therapeutics Announces U.S. Food and Drug Administration Approval of Wynzora(R) Cream (calcipotriene and betamethasone dipropionate w/w 0.005%/0.064%) for Adults with Plaque Psoriasis

Retrieved on: 
Wednesday, July 22, 2020
Steroids, RTT, Chemical compounds, Drugs, Corticosteroids, Glucocorticoids, Psoriasis, Betamethasone dipropionate, Betamethasone, Calcipotriol, Calcipotriol/betamethasone dipropionate, Plaque Psoriasis, Wynzora(R) Cream, PADTM Technology, MC2 Therapeutics

The difference in PGA treatment success to the active comparator was 14.6% (95% CI; 7.6%, 21.6%) in favor of Wynzora(R) Cream.

Key Points: 
  • The difference in PGA treatment success to the active comparator was 14.6% (95% CI; 7.6%, 21.6%) in favor of Wynzora(R) Cream.
  • "The FDA approval marks an important milestone for patients with plaque psoriasis", stated Jesper J. Lange, CEO of MC2 Therapeutics and continued: "Our PAD(TM) Technology has uniquely enabled us to develop Wynzora(R) Cream with no compromises.
  • Wynzora(R) (calcipotriene and betamethasone dipropionate) Cream is a prescription medicine indicated for the topical treatment of plaque psoriasis in patients 18 years of age and older.
  • For additional information on MC2 Therapeutics, please visit www.mc2therapeutics.com
    3 www.psoriasis.org/life-with-psoriasis/managing-itch (accessed July 13th, 2020)
    4The Voice of the Patient, Psoriasis.

MC2 Therapeutics Announces U.S. Food and Drug Administration Approval of Wynzora® Cream (calcipotriene and betamethasone dipropionate w/w 0.005%/0.064%) for Adults with Plaque Psoriasis

Retrieved on: 
Wednesday, July 22, 2020
Alternative medicine, Medical Supplies, Health, FDA, Hospitals, Clinical trials, Pharmaceutical, Steroids, RTT, Chemical compounds, Drugs, Corticosteroids, Glucocorticoids, Psoriasis, Betamethasone dipropionate, Betamethasone, Calcipotriol, Calcipotriol/betamethasone dipropionate, Plaque Psoriasis, Wynzora® Cream, PADTM Technology, MC2 Therapeutics

The difference in PGA treatment success to the active comparator was 14.6% (95% CI; 7.6%, 21.6%) in favor of Wynzora Cream.

Key Points: 
  • The difference in PGA treatment success to the active comparator was 14.6% (95% CI; 7.6%, 21.6%) in favor of Wynzora Cream.
  • The FDA approval marks an important milestone for patients with plaque psoriasis", stated Jesper J. Lange, CEO of MC2 Therapeutics and continued: "Our PAD Technology has uniquely enabled us to develop Wynzora Cream with no compromises.
  • Wynzora (calcipotriene and betamethasone dipropionate) Cream is a prescription medicine indicated for the topical treatment of plaque psoriasis in patients 18 years of age and older.
  • For additional information on MC2 Therapeutics, please visit www.mc2therapeutics.com
    3 www.psoriasis.org/life-with-psoriasis/managing-itch (accessed July 13th, 2020)
    4The Voice of the Patient, Psoriasis.